Clonal architecture of <i><scp>CXCR</scp>4 </i><scp>WHIM</scp>‐like mutations in Waldenström Macroglobulinaemia
Lian Xu(Huazhong Agricultural University), Steven P. Treon(Dana-Farber Cancer Institute), Yang Cao(Nanjing Tech University), James L. Zehnder(Cancer Prevention Institute of California), Jennifer R. Brown(Dana-Farber Cancer Institute), Jean M.G. Sabile(Stanford Medicine), Luca Arcaini(University of Pavia), Yu‐Tzu Tai(Harvard University), Sandra Kanan(University of Washington Medical Center), Jorge J. Castillo(Dana-Farber Cancer Institute), Zachary R. Hunter(Harvard University), Ruben D. Carrasco(Brigham and Women's Hospital), Kenneth C. Anderson(Dana-Farber Cancer Institute), Xia Liu(Harvard University), Nicholas Tsakmaklis(Shaanxi Research Association for Women and Family), M. Lia Palomba(Memorial Sloan Kettering Cancer Center), Ranjana H. Advani(Stanford Medicine), Alessandra Trojani(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Marzia Varettoni(Policlinico San Matteo Fondazione), Guang Yang(Blueprint Medicines (United States)), Kimon V. Argyropoulos(Memorial Sloan Kettering Cancer Center), Jie Chen(Dana-Farber Cancer Institute), Nikhil M. Munshi(Harvard University), Alessandra Tedeschi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Enrica Morra(San Antonio College), Antonino Greco(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda)
Cited by 142
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k